StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.18−0.08 (-1.10%)

Close on Nov 19, 2026Market cap $473.98MP/E –Yield –

Regenxbio net income

Net income is the profit left for shareholders after every expense, interest and tax.

Regenxbio's net income for the twelve months ending Jun 30, 2026 was -$196.43M. For fiscal 2025 it was -$193.88M. The highest annual figure on record is $127.84M in fiscal 2021.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$193.88M–
FY2024Dec 31, 2024-$227.10M–
FY2023Dec 31, 2023-$263.49M–
FY2022Dec 31, 2022-$280.32M-319.3%
FY2021Dec 31, 2021$127.84M–
FY2020Dec 31, 2020-$111.25M–
FY2019Dec 31, 2019-$94.73M-194.8%
FY2018Dec 31, 2018$99.94M–
FY2017Dec 31, 2017-$73.17M–
FY2016Dec 31, 2016-$62.97M–
FY2015Dec 31, 2015-$22.81M–
FY2014Dec 31, 2014-$4.00M–
FY2013Dec 31, 2013-$5.39M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.71M–
Q1 FY2026Mar 31, 2026-$90.05M-1580.4%
Q4 FY2025Dec 31, 2025-$67.15M–
Q3 FY2025Sep 30, 2025-$61.94M–
Q2 FY2025Jun 30, 2025-$70.87M–
Q1 FY2025Mar 31, 2025$6.08M–
Q4 FY2024Dec 31, 2024-$51.19M–
Q3 FY2024Sep 30, 2024-$59.60M–
Q2 FY2024Jun 30, 2024-$52.99M–
Q1 FY2024Mar 31, 2024-$63.33M–
Q4 FY2023Dec 31, 2023-$62.89M–
Q3 FY2023Sep 30, 2023-$61.87M–
Q2 FY2023Jun 30, 2023-$72.06M–
Q1 FY2023Mar 31, 2023-$66.68M–
Q4 FY2022Dec 31, 2022-$59.94M-120.4%
Q3 FY2022Sep 30, 2022-$75.48M–
Q2 FY2022Jun 30, 2022-$68.18M–
Q1 FY2022Mar 31, 2022-$76.72M–
Q4 FY2021Dec 31, 2021$294.02M–
Q3 FY2021Sep 30, 2021-$58.41M-764.4%
Q2 FY2021Jun 30, 2021-$57.64M–
Q1 FY2021Mar 31, 2021-$50.14M–
Q4 FY2020Dec 31, 2020-$46.24M–
Q3 FY2020Sep 30, 2020$8.79M–
Q2 FY2020Jun 30, 2020-$33.76M–
Q1 FY2020Mar 31, 2020-$40.04M–
Q4 FY2019Dec 31, 2019-$26.46M-714.6%
Q3 FY2019Sep 30, 2019-$34.58M–
Q2 FY2019Jun 30, 2019-$1.46M-113.8%
Q1 FY2019Mar 31, 2019-$32.23M-130.9%
Q4 FY2018Dec 31, 2018$4.31M–
Q3 FY2018Sep 30, 2018-$19.20M–
Q2 FY2018Jun 30, 2018$10.59M–
Q1 FY2018Mar 31, 2018$104.24M–
Q4 FY2017Dec 31, 2017-$16.00M–
Q3 FY2017Sep 30, 2017-$20.71M–
Q2 FY2017Jun 30, 2017-$14.47M–
Q1 FY2017Mar 31, 2017-$21.99M–
Q4 FY2016Dec 31, 2016-$19.61M–
Q3 FY2016Sep 30, 2016-$18.15M–

More Regenxbio figures

See a number that looks wrong?